	US 11,807,853 B2
	Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
Mariano A. Garcia-Blanco, Galveston, TX (US); Gaddiel Galarza-Munoz, Galveston, TX (US); and Shelton S. Bradrick, Galveston, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Aug. 25, 2021, as Appl. No. 17/411,265.
Application 17/411,265 is a continuation of application No. 17/027,467, filed on Sep. 21, 2020, granted, now 11,118,186.
Application 17/027,467 is a continuation of application No. PCT/US2019/023719, filed on Mar. 22, 2019.
Claims priority of provisional application 62/646,716, filed on Mar. 22, 2018.
Prior Publication US 2021/0403920 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/7088 (2006.01); A61K 45/06 (2006.01); C12Q 1/68 (2018.01)

CPC C12N 15/1138 (2013.01) [A61K 31/7088 (2013.01); A61K 45/06 (2013.01); C12N 2310/11 (2013.01); C12N 2320/31 (2013.01); C12N 2320/33 (2013.01)]

21 Claims

1. A method of treating a disease or disorder with elevated levels of a soluble isoform of an interleukin 7 receptor (sIL7R) in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising a splice-modulating antisense oligonucleotide (SM-ASO) that specifically binds to a sequence of the Interleukin-7 receptor (IL7R) pre-mRNA and increases inclusion of exon 6 in IL7R pre-mRNAs and decreases expression of the soluble isoform of IL7R (sIL7R).